RD-126

N/A

Report date: 2023/11/01 09:26:49

Base Information

Drug NameRD-126
Drug Alias NameRD-126
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, T-CellLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A